Rebirth 08: Rise from copycat phones

Chapter 339: Unexpected Anti-Cancer Drug BDF103
In a coastal country in Africa.

There is an office building with more than ten floors on the edge of the city. There is a sign in front of the building: East African Pharmaceuticals.

The locals' understanding of this company is that three years ago, an "Eastern Pharmaceutical Enterprise" from Europe invested and established a pharmaceutical company here.

What is puzzling is that this pharmaceutical company from Europe does not have a factory in the local area and hardly recruits any technical staff locally, only some low-level service staff.

In addition, there are many people from the Eastern region in this company.

As the security measures are extremely strict, their employees are almost always accompanied by security guards when they go out, which is actually quite rare in the local area.

After all, not every African country is so chaotic. At least in this small country, the overall situation is not bad, and ordinary people do not need to be accompanied by several security personnel when going out.

But considering that this is a large company from Europe, people don't find it strange.

This company called Eastern Pharmaceuticals, like many biological companies in Africa, India and other places, is actually a subsidiary of Galaxy Life Sciences. Its main mission is to conduct clinical trials of various drugs.

At present, the Eastern Pharmaceutical branch has also received orders from the headquarters to start participating in the ARE78 project and recruit test personnel to participate in the second phase of clinical trials.

Of course...in fact, most of the employees of Eastern Pharmaceutical don’t know what project they are involved in, and they don’t even know the name of the project.

They just conduct clinical trials silently, record the data, and finally feed the data back to the company headquarters.

The ARER78 project is currently the highest priority project in Galaxy Life Science. Galaxy Life Science has mobilized a large amount of resources from around the world to launch the second phase of clinical trials for this project.

The entire Phase II clinical trial will last for one year and will be carried out in eight countries or regions under different names, and it is expected to recruit more than 10,000 trial participants.

The ARE78 technology used in the Phase II clinical trial also made targeted improvements to some problems that emerged in the Phase I clinical trial, especially the obvious side effects after drug discontinuation.

The core research and development team in China has improved the technology and made subtle adjustments in order to minimize the risk of side effects and control them within a certain range, while also exploring a process for targeted treatment of side effects that occur after drug discontinuation.

After all, this kind of medicine is prepared for the rich, and obvious side effects are unacceptable. Even if certain side effects occur, they must be controlled within a certain range.

Make the overall benefits greater than the risks!

Eastern Pharmaceutical is one of the eight branches responsible for the second phase clinical trial of the ARE78 project.

In addition to the ARE78 project, Eastern Pharmaceutical is also responsible for clinical trials of more than ten other projects.

Galaxy Life's exploration of life sciences is very broad. It will try various feasible technical routes and also conducts a lot of drug research and development.

The BDF103 project is one of them. According to the R&D center of Huaxia headquarters, the core project team responsible for the development of this project hopes to achieve certain anti-aging effects by inhibiting oxygen free radicals and improving metabolism.

The core of many project teams of Galaxy Life is to "eliminate or inhibit oxygen free radicals." After all, this is the current mainstream direction of anti-aging research and development. Of course, the specific methods of each project team may be different, but the goals are the same.

The BDF103 project attempts to improve the field of metabolism. After the initial research and development of the drug for this project was completed, it was handed over to Eastern Pharmaceutical for the first phase of clinical trials.

At this time, a middle-aged East Asian man wearing glasses looked at the data on the computer and finally sighed: "It seems that it is time to end this project!"

A young girl next to him who also had an East Asian face also looked frustrated: "The preliminary experiments hardly yielded the results we wanted. All the subjects failed to see any improvement in their physical functions!"

"It's time to pack up and go back. We failed in this project!"

"Brother Liang, are we going to continue the follow-up research and development of this project this time? The project team will not be disbanded, right?"

Senior Brother Liang said, "Don't worry about this. We at Galaxy Pharmaceuticals are still very strong. We have many project teams. We don't care if there's one more or one less. The higher-ups won't stop the project. Professor Li's strength is obvious to all. It won't be a problem for him to continue to get research and development funds!"

"After all, even though this road is blocked now, it doesn't mean that the entire technical route is wrong. Strengthening immunity and improving metabolism is generally feasible. It's just that we haven't found a feasible path yet!"

As Dr. Liang spoke, he couldn't help but sigh. He has been working in this field with his mentor, Professor Li, for many years, but to be honest, there have been no practical results.

There are a lot of theories and many papers have been published, but nothing useful has been produced in more than ten years.

Because he had no practical results for a long time, it was difficult for Professor Li, whom he followed, to get funding. It was not until four years ago that he was introduced by a friend and joined Galaxy Pharmaceuticals.

After obtaining sufficient funds, he and his fellow apprentices continued their work.

However, after spending several years to come up with a technical achievement that seemed feasible in theory, it failed to pass the early stages of clinical trials.

There are no side effects, but there is no significant improvement in oxygen free radicals, and no anti-aging effect...

After four years of hard work, all was in vain. He could imagine how disappointed the teacher would be when he brought back the result.

Not only the teacher, but he himself was disappointed and helpless.

I have been engaged in research and development in the anti-aging field for more than ten years. I followed my teacher in research and development since my undergraduate stage, then graduated with a doctorate, and then continued to do it until now, but in the end I haven't made any progress... It makes people despair!
Sometimes, he even doubted whether he was cut out for drug research and development.

Looking at the junior sister next to him, he wanted to persuade her not to stick with this line of work and to change careers while she was still young!

The biopharmaceutical industry is such a bummer...

However, the words came to his lips, but he didn't say them. His junior sister was very strong, talented, and hardworking. She was his teacher's proud last disciple. If he persuaded his junior sister to run away, the teacher would probably have to clean up the mess with a broom...

Fortunately, the treatment given by Galaxy Life is good. Although there are no achievements, it does not affect the lives of people like us. It can be regarded as a blessing in disguise!
Before he joined Galaxy Life, he was just following his teacher to do research and development in the school's research institute, with a salary of only a few thousand yuan. He also had a family, so to be honest, his life was not very good.

Not to mention him, even his teacher's life is just so-so...mainly because there are no results.

In the academic world, it is very difficult to get by without any achievements. You can't even get project funds. Without project funds, there is naturally no salary. His teacher has taught many masters and doctoral students, but in the end, the number of people who stayed with him and continued to work on the anti-aging project with him, including himself and this junior sister, was only six.

The treatment is too bad and we can’t keep people!
But later, a company called Galaxy Pharmaceuticals emerged in the industry and was very interested in the teacher's project. They then made various promises, including generous salary and benefits and sufficient R&D funds.

In the end, the teacher took the six of them to Galaxy Pharmaceuticals to do research and development.

During these four years, he had lived a relatively comfortable life, with a good salary and a decent working environment. Apart from being busy with research and development every day, there was not much pressure... This was the most comfortable period in his research and development career over the past decade.

Unfortunately, after four years, we finally achieved some results, but after excitedly running to Africa for clinical trials...it was still a waste of time.

To be honest, this made him doubt his life!
At this moment, his junior sister suddenly said, "Big Brother, take a look at the physical examination data of this group of test subjects. It's quite strange!"

Dr. Liang came over and looked at the data on the computer. This was a rather special test subject as he had lung cancer.

At least this was the result of the first screening and physical examination. It was lung cancer, and it was quite serious, and it was in the late stage.

However, the results of subsequent examinations showed that there was no improvement in his physical functions and the anti-aging treatment had no effect, but his lung condition had improved a lot, and he did not look like someone in the advanced stage of lung cancer at all.

As a senior researcher who deals with drugs every day, when he saw these data for the first time, his reason told him: This is not normal.

Even though he is not specialized in anti-cancer drugs and has no research in this field, this result is not normal.

"Did our test subject receive anti-cancer treatment?"

Dr. Liang was puzzled and checked the data of the test subject in detail, but the data showed that the test subject was just an ordinary person. Not to mention cancer treatment, he didn't even know he had lung cancer before being selected for drug trials.

The project team would not sit idle and also gave him anti-cancer treatment.

He's almost dying, why treat him?
The reason why the project team continued to test the drug on him was purely for the diversification of samples...Since we were already here, we might as well just keep trying.

After all, anti-aging drugs are mostly for the elderly, who also suffer from a variety of diseases, so more aspects need to be considered. It's just that the condition of this experimental subject is not normal.

Dr. Liang thought for a moment and said, "Arrange for someone to give him a comprehensive examination. I want to see the condition of the cancer cells in his body!"

At this time, his junior sister was also a smart person. She seemed to have thought of something and said, "Brother, do you think our medicine has the potential to have anti-cancer effects?"

At this time, Dr. Liang shook his head slightly: "Ours is an anti-aging drug, aimed at inhibiting oxygen free radicals. In theory, it should not have an anti-cancer effect!"

"But since this situation has occurred, it is normal to take a look at the situation and see the results first!"

The people at Eastern Pharmaceutical quickly arranged personnel and equipment to conduct a comprehensive examination of the experimental subject, and the results were unexpected.

The cancer cells in this test subject's body were significantly reduced.

In other words, it has been greatly reduced compared to the first time I experienced it.

"Either something went wrong during the first physical examination, or something changed during the process that we're not aware of!"

Dr. Liang was already a little excited at this time: "But it doesn't matter. We will know after we conduct targeted experiments!"

Soon, Dr. Liang contacted Professor Li, his teacher in China, and reported the situation. Professor Li then continued to work and secured another opportunity for them to conduct a small-scale trial.

"Next, we will continue to conduct experiments on this subject, and at the same time select other lung cancer patients and other cancer patients to conduct experiments to see how the situation turns out!"

Although Eastern Pharmaceutical is a relatively unknown company in the local area, it has always relied on money to pave the way for clinical trials. It took only a few days to arrange hospitals and test personnel to start a new round of clinical trials.

Ten days after the trial began, preliminary data came out.

Then Dr. Liang looked at the data above with mixed feelings... In the new round of trials, this BDF103 drug still had no anti-aging effect and was completely useless.

However, it seems to have a very good anti-cancer effect.

Almost all of the fifty test subjects were in the advanced stage of cancer. After taking the medicine for ten consecutive days, the cancer condition in their bodies improved significantly. Although it did not reach the level of directly curing the cancer cells, it also improved significantly.

The drug also demonstrates wide-ranging applicability. In addition to the lung cancer that was initially discovered, it also has varying degrees of therapeutic effects on cancer cells of several other cancers.

"So, the anti-aging drugs we developed eventually became anti-cancer drugs? And there are no obvious side effects." The junior sister next to her was very excited.

"We are successful, right?"

Dr. Liang has mixed feelings...

Is this a success or a failure?

As a person who has been engaged in anti-aging research for a lifetime, to put it more extremely, he only has eyes for research in the field of anti-aging, and that is all he knows.

It was almost becoming his obsession.

Just like his teacher, he devoted his whole life to this field!

Otherwise, he would have already switched to some other pharmaceutical companies to engage in general drug research and development. With his qualifications and experience, he could easily get a high salary.

But he still followed his teacher and continued to work hard in the anti-aging field just for this obsession.

As for the field of anti-cancer, he doesn’t care, he doesn’t care... He only cares about the field of anti-aging!

But after half a lifetime of hard work and countless sleepless nights, BDF103 was finally developed, and it turned out to be an anti-cancer drug?
Dr. Liang didn’t know whether to be happy or cry!

This life is so fucking fucked up...

--------

The BDF103 project was originally intended for anti-aging, but it turned out to have anti-cancer effects and good adaptability, with very good effects on the five types of cancer in the experimental group.

This result was quickly reported and finally fed back to Xu Shenxue.

"Anti-cancer drugs? That's pretty good too!" Xu Shenxue did not have the obsession that Dr. Liang and his apprentice had. No matter what results Galaxy Life developed, as long as they were useful, it was a good thing.

Xu Shenxue read the report carefully, and then instructed Galaxy Life: "It seems that there are no obvious side effects, so continue the experiment and get an accurate result as soon as possible!"

"By the way, this project is different from the ARF78 project. If it is feasible, it will still be marketed to the public. After the preliminary trials are completed, public clinical trials will be launched as soon as possible to see the results."

If all goes well, the BDF103 drug will likely become Galaxy Pharmaceuticals' first commercial product.

Following Xu Shenxue's instructions, Galaxy Life Science Headquarters soon arranged the testing of the BDF103 project, and good results were reported only one month later.

Fang Yulin, the head of Galaxy Life and CEO of Galaxy Life, personally reported this achievement to Xu Shenxue.

"In the one-month first phase clinical trial, we conducted trials on 3,000 patients with different types of cancer. Ninety-five percent of the patients achieved good treatment results. Some of the patients with relatively mild cancer had their cancer cells completely eliminated and recovered."

“Some patients with moderate cancer have also shown significant improvement, and according to our expectations, they can be cured after continuing to take the medication for about a year!”

"And some critically ill patients have also achieved significant improvement through a combination of surgical treatment and medication."

"It has obvious therapeutic effects on common cancers such as lung cancer, liver cancer, stomach cancer, colorectal cancer, etc."
"Based on the results of the first phase of clinical trials and the extensive pharmacological studies conducted by the R&D team on the drug, we all agree that the BDF103 project has very good prospects. We even think that formal clinical trials can be carried out in conventional countries or even in China!"

"After all, we did not find any obvious side effects of the drug in the first phase of clinical trials."

“There is no need to worry about any legal issues, and the project has very good business prospects!”

Fang Yulin was very excited when he said this... As the head of a large biological group with a certain degree of secrecy, Fang Yulin was actually under a lot of pressure.

The company spends more than ten or twenty billion dollars every year on research and development, but in the past few years, there has been no formal results and no income at all. All the company's expenses, especially the huge drug research and development, have to rely on external funds.

Even though the company is a non-profit organization in a sense, a number of investors, including the boss Xu Shenxue, do not require the company to make a profit, and do not even have any requirements for the company's commercialization.

But even so, he was under a lot of pressure.

God knows when these rich people will stop investing money... If they stop investing money, the company will be dissolved in minutes.

He, the CEO, will also lose his job!

Therefore, even though Xu Shenxue and other investors have no requirements for the company's commercialization, let alone requiring the company to make money, he still very much hopes that the company can produce a drug with commercial value and thus maintain the healthy operation of the company.

Now the unexpected success of the BDF103 project has given him this hope!

Xu Shenxue said: "In this case, let's start formal clinical trials, both domestically and abroad, and see how it goes!"

Now that the anti-cancer drug has been developed and the effect seems to be quite good, Xu Shenxue is naturally happy to launch this drug to give cancer patients and their families new hope!
Hope to survive!

Save broken families!
So he thought about it and said, "During the formal clinical trial, more domestic quotas will be allocated!"

"Since it's a good thing, keep more for your family!"

(End of this chapter)